Upstate Active Clinical Trials

Study Title:

AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Upstate Institutional Review Board (IRB) Number:

1521725

Study/Protocol ID:

AALL1732

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Philip Monteleone

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again